Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety...

Area of Science:

• Regenerative Medicine
• Endocrinology
• Clinical Trials

Background:

• Type 2 diabetes is a growing global health concern.
• Current treatments often require multiple medications and lifestyle changes.
• Mesenchymal precursor cells (MPCs) are being investigated for their therapeutic potential in metabolic diseases.

Purpose of the Study:

• To evaluate the safety, tolerability, and feasibility of allogeneic bone marrow-derived MPCs (rexlemestrocel-L) in adults with type 2 diabetes.
• To assess the efficacy of MPCs in improving glycemic control as measured by HbA1c levels.

Main Methods:

• A dose-escalating, randomized, placebo-controlled trial was conducted.
• Participants received one intravenous infusion of MPCs at doses of 0.3, 1.0, or 2.0 × 10^6/kg, or a placebo.
• The study duration was 12 weeks, with safety and efficacy assessments throughout.

Main Results:

• The infusion of rexlemestrocel-L was found to be safe and well-tolerated, with no acute adverse events or serious adverse events reported.
• Compared to placebo, a single IV infusion of rexlemestrocel-L led to reductions in HbA1c levels starting from week 1.
• The highest dose (2.0 × 10^6/kg) resulted in a statistically significant reduction in HbA1c at 8 weeks and enabled 33% of patients to reach the target HbA1c <7%.

Conclusions:

• This study demonstrates the short-term safety and feasibility of administering up to 246 million MPCs (rexlemestrocel-L) to patients with type 2 diabetes.
• Rexlemestrocel-L shows potential as a novel therapeutic option for improving glycemic control in type 2 diabetes.
• Further research is warranted to explore the long-term efficacy and optimal dosing of MPCs in this patient population.